Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors.

Theranostics - 1 Jan 2021

Shi Zhiwen, Shen Jianfeng, Qiu Junjun, Zhao Qingguo, Hua Keqin, Wang Hongyan

Abstract excerpt

Background: Homologous recombination deficiency (HRD) is a common molecular characteristic of genomic instability, and has been proven to be a biomarker for target therapy. However, until now, no research has explored the changes in the transcriptomics landscape of HRD tumors. Methods: The HRD score was established from SNP array data of breast cancer patients from the cancer genome atlas (TCGA) database. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine CXCL10
Share to Databases, Nucleic Acid
Share to Genomic Instability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homologous Recombination

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Neoplasm Proteins

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34158843
DOI: 10.7150/thno.59056
PMCID: PMC8210593

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors.PMID 34158843Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.Semantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

Integrative Analysis of Homologous Recombination Repair Patterns Unveils Prognostic Signatures and Immunotherapeutic Insights in Breast CancerSemantic proximity Read ↗

Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer.Semantic proximity Read ↗

Somatic mutations in homologous recombination pathway predict favorable prognosis after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinomaSemantic proximity Read ↗

Impact of Typical Somatic Gene Mutation Characteristics on Homologous Recombination Deficiency in Breast Cancer.Semantic proximity Read ↗

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast CancerSemantic proximity Read ↗

Identification of a Novel Gene Model-Based Homologous Recombination Deficiency Score to Improve Survival Prediction of TNBC.Semantic proximity Read ↗

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature ReviewSemantic proximity Read ↗

Homologous recombination deficiency reflects the heterogeneity and monitoring treatment response for patients with breast cancer.Semantic proximity Read ↗

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.